This segment is sponsored by Eli Lilly and Company.In the U.S., approximately 24 million adults suffer from moderate-to-severe obstructie sleep apnea, or OSA.

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Late-breaking results from Eli Lilly and Company (NYSE ... prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity.1 Zepbound may help adults with ...

Opens in a new tab or window The FDA recently approved the first drug specifically for treating moderate-to-severe obstructive sleep apnea ... with NovoNordisk, Eli Lilly, Endorsia Pharmaceuticals ...

Chemically known as tirzepatide, Mounjaro is currently sold in the UK and Europe under the same brand name for both diabetes ...

US pharma major Eli Lilly has launched in India its eagerly awaited diabetes and obesity drug Mounjaro tripeptide Read ahead ...

India, with over 101 million diabetes patients and rising obesity rates, faces a critical need for effective treatment ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

Eli Lilly and Co. has begun selling its blockbuster weight-loss and diabetes drug Mounjaro in India, pipping rivals in a ...

Eli Lilly says it is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP and ...

The much-awaited launch of Mounjaro, an injectable drug used to treat obesity, overweight, and type 2 diabetes, has been ...

Eli Lilly and Company (India) on Thursday said it has launched a first-of-its-kind medication for obesity and type 2 diabetes ...